SCHEMBL1128638

SCHEMBL1128638

Oc1cccc(O)c1/N=N/c1ccccn1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.65
MAPT P10636 4/20 0.65
ALDH1A1 P00352 3/20 0.65
KDM4E B2RXH2 2/20 0.65
OPRK1 P41145 2/20 0.65
HTT P42858 2/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
NPSR1 Q6W5P4 2/20 0.65
TDP1 Q9NUW8 2/20 0.65
L3MBTL1 Q9Y468 2/20 0.65
HPGD P15428 2/20 0.65
NPC1 O15118 1/20 0.65
POLB P06746 1/20 0.65
HSP90AA1 P07900 1/20 0.65
ALOX12 P18054 1/20 0.65
MAOA P21397 2/20 0.57
MAOB P27338 2/20 0.57
ADRA2A P08913 2/20 0.52
ADRA2B P18089 2/20 0.52
ADRA2C P18825 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1128642 1.00 LMNA (0.65) LMNAMAPTALDH1A1KDM4EOPRK1
SCHEMBL10790402 0.98 LMNA (0.63) LMNAMAPTALDH1A1KDM4EOPRK1
SCHEMBL591141 0.98 LMNA (0.63) LMNAMAPTALDH1A1KDM4EOPRK1
SCHEMBL591140 0.98 LMNA (0.63) LMNAMAPTALDH1A1KDM4EOPRK1
SCHEMBL10790408 0.98 LMNA (0.63) LMNAMAPTALDH1A1KDM4EOPRK1
SCHEMBL2470956 0.82 MAOA (0.77) LMNAMAPTALDH1A1KDM4EOPRK1
SCHEMBL275526 0.82 MAOA (0.77) LMNAMAPTALDH1A1KDM4EOPRK1
SCHEMBL29785641 0.82 MAOA (0.77) LMNAMAPTALDH1A1KDM4EOPRK1
SCHEMBL1933506 0.82 KDM4E (0.61) LMNAMAPTALDH1A1KDM4EOPRK1
SCHEMBL2218613 0.82 KDM4E (0.61) LMNAMAPTALDH1A1KDM4EOPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020187558-A1 Method for determining the amount of metal in water and kit therefor ADVANCED EXPLORATION & RESEARCH, INC. 2002-12-12 US claimed
US-4681828-A Method of chemical electrographic image amplification using chemically active toner particles EASTMAN KODAK COMPANY (US) 1987-07-21 US claimed
US-4084967-A Photographic elements containing vesicles of rhodopsin and lipids EASTMAN KODAK COMPANY (US) 1978-04-18 US claimed
US-4057427-A PHOTOGRAPHY EASTMAN KODAK COMPANY (US) 1977-11-08 US claimed
US-20170209400-A1 METHODS AND TOPICAL FORMULATIONS FOR TREATING INFLAMMATION LIVIONEX INC (US) 2017-07-27 US disclosed
US-9616127-B2 Method and topical formulation for treating localized edema LIVIONEX INC. (US) 2017-04-11 US disclosed
US-9614165-B2 Photoelectric conversion element, dye-sensitized solar cell, metal complex dye, dye solution, dye-adsorbed electrode and method of producing dye-sensitized solar cell FUJIFILM CORPORATION (JP) 2017-04-04 US disclosed
EP-2933875-B1 PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, METAL COMPLEX DYE, DYE SOLUTION, DYE-ADSORBED ELECTRODE, AND METHOD FOR PRODUCING DYE-SENSITIZED SOLAR CELL FUJIFILM CORP (JP) 2017-03-29 EP disclosed
EP-2933875-A1 PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, METAL COMPLEX DYE, DYE SOLUTION, DYE-ABSORBED ELECTRODE, AND METHOD FOR MANUFACTURING DYE-SENSITIZED SOLAR CELL Fujifilm Corporation (JP) 2015-10-21 EP disclosed
US-20150280145-A1 PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, METAL COMPLEX DYE, DYE SOLUTION, DYE-ABSORBED ELECTRODE AND METHOD OF PRODUCING DYE-SENSITIZED SOLAR CELL FUJIFILM CORPORATION (JP) 2015-10-01 US disclosed
EP-2282729-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION AND INFLAMMATION-RELATED PATHOLOGIES Livionex Inc. (US) 2011-02-16 EP disclosed
US-20100069335-A1 Prevention and Treatment of Ophthalmic Complications of Diabetes LIVIONEX INC. 2010-03-18 US disclosed
EP-1146062-A1 Method of producing crosslinkable silyl group-containing polyoxyalkylene polymers Kaneka Corporation (JP) 2001-10-17 EP disclosed
US-6022879-A TREATING AMYOTROPHIC LATERAL SCLEROSIS; NEOCUPROINE UAB RESEARCH FOUNDATION (US) 2000-02-08 US disclosed
WO-1999018958-A1 BATHOCUPROINE TREATMENT OF NEUROLOGIC DISEASE UAB RESEARCH FOUNDATION (US) 1999-04-22 WO disclosed
EP-0382400-A2 Immunoassay process and liquid reagents used therefor WAKO PURE CHEMICAL INDUSTRIES LTD (JP) 1990-08-16 EP disclosed
US-4681828-A Method of chemical electrographic image amplification using chemically active toner particles EASTMAN KODAK COMPANY (US) 1987-07-21 US disclosed
US-4131463-A Electric recording process of images using electron sensitive layer containing trivalent cobalt complex and compound having conjugated π bond system FUJI PHOTO FILM CO., LTD. (JP) 1978-12-26 US disclosed
US-4084967-A Photographic elements containing vesicles of rhodopsin and lipids EASTMAN KODAK COMPANY (US) 1978-04-18 US disclosed
US-4057427-A PHOTOGRAPHY EASTMAN KODAK COMPANY (US) 1977-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069335-A1 Prevention and Treatment of Ophthalmic Complications of Diabetes SLC5A1, SLC2A8, SMS LMNA 2101/4885MAPT 4436/4885ALDH1A1 2737/4885
US-20170209400-A1 METHODS AND TOPICAL FORMULATIONS FOR TREATING INFLAMMATION MMP8, CXCL8, MMP1 LMNA 4562/4885MAPT 3632/4885ALDH1A1 4592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.